Tag: health

Gluten-Free Bakery Market Fueled by Growing Popularity of Plant-Based Ingredients

The global gluten-free bakery market was valued at USD 1.64 billion in 2021 and is projected to expand at a compound annual growth rate (CAGR) of 10.8% from 2022 to 2030. A key factor driving this growth is the rising demand for healthy and nutritious food products, fueled by increasing health awareness worldwide. Additionally, the growing interest in health-focused diets aimed at preventing conditions such as heart disease, diabetes, obesity, chronic pulmonary disease (COPD), and metabolic syndrome is expected to further propel market expansion. New product launches by manufacturers are also playing a significant role in supporting industry growth.

The COVID-19 pandemic led to a surge in demand for healthier food options, including gluten-free bakery products, further strengthening the market. During the pandemic, healthcare professionals recommended the regular consumption of nutritious foods to enhance immunity. With consumers spending more time at home, interest in personal health and fitness grew, boosting sales of gluten-free bakery products like bread, cookies, and biscuits. Moreover, the high global incidence of celiac disease continues to drive product demand.

According to the Celiac Disease Foundation, the prevalence of celiac disease in 2018 was 0.4% in South America, 0.5% in Africa and North America, 0.6% in Asia, and 0.8% in Europe and Oceania. Celiac disease is commonly managed through a gluten-free diet, which helps prevent damage to the intestinal lining and reduces symptoms like diarrhea and abdominal pain. As a result, rising demand for gluten-free products for celiac disease management is accelerating industry growth. Gluten-free bakery items are also gaining popularity among individuals with other health conditions, including inflammatory diseases, autoimmune disorders, and non-celiac gluten sensitivity.

Furthermore, increasing government awareness campaigns promoting gluten-free products for the treatment of celiac and non-celiac conditions are contributing to market growth. These initiatives have raised awareness around celiac disease diagnosis and stimulated product demand. Additionally, the growing trend of healthy eating in developing regions is expected to create further opportunities for market expansion. The adoption of microencapsulation technology to enhance the shelf life of gluten-free bakery products is also expected to drive growth. This technology helps improve both shelf life and texture, particularly in frozen gluten-free baked goods. Consequently, the strong demand for frozen gluten-free bakery items continues to fuel market growth. The availability of diverse product options, along with continuous innovations, is anticipated to positively influence market expansion.

Product Insights

In 2021, the bread segment accounted for the largest market share, contributing more than 36.30% of the total. This dominance is attributed to strong demand for low-carb gluten-free bread, rye bread, wheat-free bread, and similar products, due to their associated health benefits. Gluten-free bread caters to the growing need for convenient and quick meals, especially among working individuals. The ability to customize bread to meet specific dietary needs is also expected to boost this segment. Additionally, increasing consumption of gluten-free bread by individuals with celiac disease further supports segment growth.

Distribution Channel Insights

In 2021, the supermarkets and hypermarkets segment led the market, capturing over 34.00% of global revenue. These retail formats offer a wide selection of products and allow consumers to review product details before purchasing, driving segment growth. A robust offline retail infrastructure in countries like the U.S., China, and India has further bolstered sales of gluten-free bakery products through supermarkets and hypermarkets. The broad availability of healthy food products in these retail outlets has fueled overall sales. Moreover, consumers continue to prefer traditional supermarkets for their convenience and extensive product offerings, contributing to this segment’s expansion.

Get a preview of the latest developments in the Gluten-Free Bakery Market! Download your FREE sample PDF today and explore key data and trends

Regional Insights

North America held the largest market share, contributing over 33.90% of global revenue in 2021, and is expected to maintain its dominance throughout the forecast period. Growth in this region is largely driven by the substantial number of consumers diagnosed with celiac disease. According to a Celiac Disease Foundation survey, approximately 0.6% of the U.S. population is affected by celiac disease. Additionally, strong demand for healthy and nutritious food products in the U.S. and Canada has supported market growth. Increasing interest from millennials and younger consumers in convenient, healthy food options with high nutritional value has further fueled expansion in this region.

Key Market Players

Leading companies in the global gluten-free bakery market include:

  • Amy’s Kitchen
  • Bob’s Red Mill Natural Foods, Inc.
  • Dawn Food Products
  • The Hain Celestial Group
  • Dr. Schar AG
  • Freedom Nutritional Products Ltd.
  • General Mills
  • Conagra Brands
  • Valeo Foods Ltd.
  • WGF Bakery Products
  • Europastry S.A.
  • Kelkin

Gather more insights about the market drivers, restrains and growth of the Gluten-Free Bakery Market

Bioanalytical Testing Services Market Fueled by Increasing Focus on Biomarker Testing

The global bioanalytical testing services market was valued at USD 4.73 billion in 2024 and is anticipated to expand at a CAGR of 9.21% from 2025 to 2030. This growth is driven by the rising volume of drug development activities, increasing drug approval processes, growing therapeutic complexity, and a surge in outsourcing of testing services. The emergence of complex therapeutic modalities—such as gene therapies and biologics—has heightened the demand for specialized bioanalytical testing services. Additionally, technological advancements and rising investments in research and development are key contributors to market expansion.

The continuous evolution of advanced technologies—including High-Throughput Screening (HTS), Liquid Chromatography-Mass Spectrometry (LC-MS), and Next-Generation Sequencing (NGS)—has significantly enhanced the accuracy, speed, and sensitivity of bioanalytical testing. These innovations empower service providers to conduct more sophisticated studies and obtain precise data regarding drug efficacy, safety, pharmacokinetics, and more. Furthermore, the integration of automation and Artificial Intelligence (AI) within bioanalytical workflows has streamlined operations, minimized human error, and boosted throughput.

Moreover, heightened regulatory oversight and growing awareness of the critical role of bioanalytical testing are also fueling demand for these services. The implementation of stricter guidelines governing drug development—especially in pharmacokinetics, pharmacodynamics, and bioequivalence testing—by regulatory agencies like the U.S. FDA and EMA has led to a stronger inclination toward outsourcing. These regulations emphasize the necessity for accurate, reliable bioanalytical methods to ensure the safety and effectiveness of new drugs and biosimilars.

Pricing Analysis

The bioanalytical testing services sector utilizes various pricing models tailored to specific project requirements and levels of client engagement. Milestone-based pricing is widely adopted for projects with clearly defined stages, such as method development and sample analysis, enabling payments to be linked with the achievement of deliverables. This approach provides predictability for sponsors while aligning payments with progress for service providers. Fixed-fee pricing is more suitable for routine testing services—including bioequivalence and pharmacokinetic studies—where standardization leads to minimal variability.

Get a preview of the latest developments in the Bioanalytical Testing Services Market! Download your FREE sample PDF today and explore key data and trends

Molecule Insights

The small molecule segment held the largest market share at 55.3% in 2024. This dominance is attributed to breakthroughs in small molecule therapeutics and persistent unmet medical needs. Bioanalytical testing of small molecules plays a pivotal role in understanding their ADME (Absorption, Distribution, Metabolism, and Excretion) profiles, determining appropriate dosing, evaluating therapeutic efficacy, and ensuring patient safety.

Test Insights

In 2024, the bioavailability segment led the market. Its growth stems from its vital role in drug development and regulatory approval processes. Bioavailability studies are essential for assessing how effectively and rapidly a drug reaches systemic circulation, directly impacting dosage formulation, therapeutic efficacy, and safety. This segment is crucial for evaluating both new chemical entities and generic formulations to ensure consistent performance and compliance with bioequivalence standards.

Workflow Insights

The sample analysis segment was the dominant workflow category in 2024. This segment encompasses processes such as quantification of active pharmaceutical ingredients, metabolite detection, and stability testing—each critical for regulatory submissions and clinical trial advancement. As drug pipelines become more complex, especially with the rise of biologics and targeted therapies, demand for accurate, high-throughput sample analysis is expected to increase.

End Use Insights

In 2024, the pharma & biopharma companies segment accounted for the largest market share. This growth reflects the increasing reliance on outsourcing specialized testing throughout the drug development lifecycle. Pharmaceutical and biopharmaceutical companies are increasingly turning to external service providers to navigate the complex, highly regulated bioanalytical workflows—including pharmacokinetic assessments, immunogenicity testing, and biomarker validation. Outsourcing enables these companies to accelerate development timelines, reduce internal infrastructure costs, and access specialized expertise and advanced technologies.

Regional Insights

North America represented the largest share of the global bioanalytical testing services market, accounting for 47.40% in 2024. Growth in this region is propelled by rising demand for biopharmaceuticals, continuous technological innovation, and increased R&D investment in novel drug development. Advancements in mass spectrometry, chromatography, and other analytical techniques have further improved the sensitivity, specificity, and throughput of bioanalytical testing. These innovations enable laboratories to conduct more precise and efficient analyses, supporting faster drug development timelines and lowering costs.

Leading Companies in the Bioanalytical Testing Services Market

The following companies are key players in the bioanalytical testing services market, collectively holding a significant share and shaping industry trends:

  • Thermo Fisher Scientific Inc.
  • ICON Plc
  • Charles River Laboratories International
  • IQVIA Inc.
  • Syneos Health
  • SGS SA
  • Labcorp
  • Intertek Group Plc
  • Pace Analytical Services LLC
  • WuXi AppTec

Gather more insights about the market drivers, restrains and growth of the Bioanalytical Testing Services Market

Pathology Laboratories Market Gains Momentum with Increasing Cancer Screening

The global pathology laboratories market was valued at USD 386.18 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.1% from 2025 to 2030. This growth is primarily fueled by the expansion of healthcare facilities in developing regions, rising demand for routine medical examinations, and improvements in reimbursement policies for diagnostic tests. Additional drivers include an aging global population and the increasing prevalence of chronic diseases. Moreover, the market is benefiting from the establishment of new laboratories in emerging markets. For example, in August 2024, Neuberg Diagnostics launched a new laboratory facility in Puducherry, India, offering radiology, wellness, and pathology services.

As chronic diseases become more widespread, the demand for robust healthcare systems and timely diagnostics continues to rise. Early and accurate diagnosis is essential for effective management of chronic conditions, leading to greater reliance on clinical diagnostics. According to the World Health Organization, the global senior population is expected to increase from 1 billion in 2020 to 1.5 billion by 2030, with one in six people worldwide aged 60 or older. Chronic illnesses are especially common among older adults; the National Council on Aging reports that 80% of U.S. adults aged 65 and above have at least one chronic condition, emphasizing the critical need for regular health screenings in this age group.

The trend toward routine health check-ups is also on the rise. Given the high incidence of chronic conditions, individuals over 40 are strongly encouraged to undergo regular health screenings. Meanwhile, the growing occurrence of chronic diseases among younger adults has led to increased demand for preventive check-ups within this demographic. Heightened health awareness has motivated more individuals to prioritize routine medical evaluations.

In addition, many countries require employers to provide annual health assessments for their employees, creating further demand for diagnostic laboratory services. Increased healthcare spending aimed at improving infrastructure in developing nations has also contributed to the establishment of new hospitals and diagnostic labs, along with upgrades to existing facilities. For instance, in March 2022, the Delhi government announced plans to upgrade 15 hospitals and build four new hospitals in the city, boosting the expansion of hospital-based diagnostic centers.

Type Insights
In 2024, the hospital-based segment led the market, accounting for 55.7% of total revenue. The growth of hospital-based laboratories is driven by several factors: the rising burden of chronic diseases necessitating prompt and accurate diagnostics; technological advancements that enhance testing efficiency and accuracy; and the growing emphasis on patient-centered care, encouraging integration of laboratory services with clinical operations to improve outcomes. Furthermore, favorable reimbursement policies and the increasing demand for routine health screenings continue to support the expansion of hospital-based labs within healthcare systems.

Testing Services Insights
The general physiological and clinical tests segment held the largest market share in 2024, representing 39.2% of the total. These tests—including blood counts, metabolic panels, and urinalysis—are fundamental tools for diagnosing diverse health conditions and monitoring patient health. Their broad use across primary care, outpatient clinics, and hospitals sustains steady demand, as they are vital for early disease detection and effective treatment planning.

Get a preview of the latest developments in the Global Pathology Laboratories Market! Download your FREE sample PDF today and explore key data and trends

End-use Insights
In 2024, physician referrals accounted for 51.7% of the overall market share. Approximately 70% of physicians’ medical decisions depend on diagnostic and pathological test results, underscoring the critical role of laboratory testing in clinical decision-making. The increasing prevalence of targeted diseases across various age groups is expected to further drive the growth of this segment.

Regional Insights
North America dominated the global pathology laboratories market in 2024, capturing a 37.87% revenue share. The region’s leadership is attributed to its advanced healthcare infrastructure, high adoption of innovative diagnostic technologies, and well-established regulatory environment. Additionally, rising rates of chronic diseases, growing demand for personalized medicine, and increasing healthcare expenditures contribute to North America’s prominent position in the global market.

Key Pathology Laboratories Companies
The leading companies shaping the pathology laboratories market include:

  • Quest Diagnostics Incorporated
  • Eurofins Scientific
  • Laboratory Corporation of America Holdings
  • Exact Sciences Laboratories LLC
  • Spectra Laboratories
  • SYNLAB International GmbH
  • Sonic Healthcare Limited
  • Dr. Lal Path Labs
  • Metropolis Healthcare
  • Kingmed Diagnostics
  • Healius Limited
  • BioReference
  • Centro de Diagnósticos
  • Falco Holdings
  • Unilabs

Gather more insights about the market drivers, restrains and growth of the Pathology Laboratories Market

Medical Equipment Maintenance Market Driven by Strict Regulatory Compliance Needs

The global medical equipment maintenance market was valued at USD 41.90 billion in 2023 and is projected to expand at a CAGR of 10.0% from 2024 to 2030. The market’s growth is driven by the rising global demand for medical devices, the increasing prevalence of life-threatening conditions requiring diagnostic procedures, and the growing need for refurbished medical equipment.

Given the critical role of medical equipment in healthcare delivery, the effectiveness of treatments largely depends on the precision and performance of these devices. A wide range of equipment—such as electrocardiographs, syringe pumps, centrifuges, X-ray machines, autoclaves, and ultrasound devices—are used across healthcare settings for diagnosis and treatment. Due to continuous use, these devices require regular maintenance to address wear, malfunctions, and potential defects.

In 2023, imaging equipment led the market, accounting for 36.1% of total market share. Imaging devices are essential for visualizing internal body structures and facilitating accurate diagnosis. The rising incidence of chronic conditions, particularly cardiovascular diseases, is fueling demand in this segment. According to the Centers for Disease Control and Prevention, approximately 129 million people in the U.S. suffer from at least one major chronic disease. Common imaging modalities include X-rays, magnetic resonance imaging (MRI), computed tomography (CT) scans, and ultrasound.

Service Insights

The corrective maintenance segment held the largest revenue share in 2023. This segment focuses on repairing equipment following malfunctions or failures, restoring systems to their original working condition through replacement or restoration efforts. The increasing frequency of equipment breakdowns—stemming from constant use in modern healthcare facilities—is expected to drive rapid growth in this area.

Service Provider Insights

In 2023, the Original Equipment Manufacturer (OEM) segment captured the highest revenue share. OEMs provide highly specialized maintenance services tailored to their products, leveraging their deep understanding of the equipment’s design, components, and functionality. By offering post-warranty maintenance and repair services, OEMs not only generate additional revenue but also strengthen long-term relationships and foster customer loyalty.

Get a preview of the latest developments in the Global Medical Equipment Maintenance Market! Download your FREE sample PDF today and explore key data and trends

End-Use Insights

The hospital segment accounted for the largest revenue share in 2023. An aging global population is contributing to a rise in chronic diseases such as diabetes, heart disease, and cancer, driving the need for advanced diagnostic and therapeutic equipment. Private hospitals are investing in state-of-the-art devices to enhance patient care and attract more patients. Additionally, increased government spending on healthcare infrastructure continues to bolster the demand for sophisticated medical equipment.

Regional Insights

In 2023, North America dominated the global medical equipment maintenance market. Factors such as advancements in medical infrastructure, a growing burden of chronic illnesses, increased healthcare spending, and the presence of ambulatory surgical centers are fueling market growth in the region. North America’s strong healthcare sector and its growing role in medical tourism have sustained demand for reliable, fully operational medical equipment.

Leading Companies in the Medical Equipment Maintenance Market

The key players shaping the medical equipment maintenance market include:

  • GE HealthCare
  • Siemens Healthineers AG
  • Medtronic
  • Aramark
  • Koninklijke Philips N.V.
  • B. Braun SE
  • AlphaSource Group
  • Althea Group

Gather more insights about the market drivers, restrains and growth of the Medical Equipment Maintenance Market

Brain Health Supplements Market Trends Reflect Shift Toward Preventive Healthcare

The global brain health supplements market reached a valuation of USD 8.63 billion in 2022 and is projected to expand at a compound annual growth rate (CAGR) of 13.3% from 2023 to 2030. This growth is largely driven by increasing awareness around mental health concerns, including attention deficits, memory decline, anxiety, and depression. Additionally, a rising preference for natural and herbal health remedies is expected to further propel market expansion during the forecast period. The growing demand for multifunctional supplements that act as energy boosters, antidepressants, cognitive enhancers, and anxiety relievers is likely to stimulate more research and development in this space. Furthermore, heightened interest from the sports industry in improving cognitive performance among athletes is anticipated to create new growth opportunities.

Individuals involved in academic and professional settings are expected to significantly contribute to the rising demand for brain health supplements in the coming years. These products are also expected to gain traction among people dealing with various neurological conditions such as depression, dementia, anxiety, and insomnia.

A report by the World Health Organization (WHO) published in September 2021 highlighted that approximately 280 million people worldwide of all age groups suffer from depression. In the United States, anxiety disorder is one of the most prevalent mental health conditions.

According to an October 2022 report by the Anxiety & Depression Association of America, about 19.1% of U.S. adults—equivalent to 40 million individuals—experience anxiety. As awareness of mental health issues continues to grow, the application scope for brain health supplements is expected to broaden accordingly.

These supplements are also being used to manage other cognitive and age-associated conditions, including hyperactivity and Parkinson’s disease. Growing concern about mental wellness and cognitive health is anticipated to support continued market growth.

Memory-enhancing brain supplements recorded the highest market penetration in 2022. Heightened competition in both educational and professional environments has fueled demand for these products. Moreover, the increasing need to support memory retention among aging populations has further boosted market interest.

Consumers are also drawn to these supplements due to their affordability and ease of access, which are expected to continue driving product adoption and segment growth.

Initially focused on aging baby boomers aiming to delay or prevent cognitive decline, cognitive enhancement supplements are now also being marketed toward millennials, a generation frequently seeking productivity-boosting solutions under high-pressure conditions.

Get a preview of the latest developments in the Global Brain Health Supplements Market! Download your FREE sample PDF today and explore key data and trends

Regional Insights
North America led the global market in 2022, accounting for over 40.1% of the total share. Demand in the region has seen notable growth, spurred by increasing health consciousness and rising interest in cognitive wellness products, particularly among younger consumers.

A survey by the American Association of Retired Persons (AARP) in June 2019 revealed that a large segment of Americans aged 50 and older regularly consume brain health supplements, primarily driven by concerns over cognitive decline and brain health.

Meanwhile, the Asia Pacific region is projected to experience the fastest growth, with a CAGR of 15.8% from 2023 to 2030. This surge is attributed to heightened awareness of supplement benefits, a preference for natural over pharmaceutical options, and a growing incidence of Alzheimer’s in countries like China, India, and Japan.

Key Players in the Global Brain Health Supplements Market Include:

  • Natural Factors Nutritional Products Ltd
  • Onnit Labs, Inc.
  • Purelife Bioscience Co., Ltd
  • Intelligent Labs
  • Accelerated Intelligence Inc.
  • NOW Foods
  • HVMN Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Peak Nootropics
  • Alternascript

Gather more insights about the market drivers, restrains and growth of the Brain Health Supplements Market

Gene Therapy Market Propelled by Innovation in Viral and Non-Viral Vectors

The global gene therapy market was valued at USD 5.54 billion in 2023 and is anticipated to expand at a compound annual growth rate (CAGR) of 18.88% from 2024 to 2030. This growth is driven by several key factors, including the rising advancement in therapeutic technologies and gene delivery methods, as well as intensifying competition among major industry players aiming to commercialize their therapies. Biotechnology firms are actively pursuing mergers, acquisitions, collaborations, and strategic partnerships to build internal expertise and strengthen their product pipelines.

The COVID-19 pandemic had an adverse impact on market performance. The industry faced significant disruptions in supply chains, production capabilities, and logistics operations. For example, certain companies experienced prolonged delays in obtaining specific components and later encountered shortages in clinical trial supplies after one of their contract manufacturing partners was forced to cease operations.

Despite this, the market is expected to gain momentum in the coming years, supported by a strong development pipeline. Researchers are striving to bring gene therapy into routine clinical practice. Numerous academic institutions and research centers have an extensive range of products under development, which is projected to contribute to revenue growth throughout the forecast period. Notably, clinical trials for gene therapy surged following the FDA’s approval of the first gene therapy in 2017. According to the American Society of Gene & Cell Therapy (ASGCT), there are currently approximately 1,986 gene therapy-related products in development, including CAR T-cell therapies and other genetically engineered cell treatments.

In addition, evolving regulatory frameworks are expected to foster further growth. Several global regulatory agencies have implemented positive changes to facilitate the advancement of gene therapies. For instance, the FDA has expressed strong support for CAR-T cell technology. During Phase II and III clinical studies, regulators are showing increased flexibility in the traditional trial structure. The FDA anticipates approving between 10 and 20 new gene therapies annually by 2025.

Increased funding and investment in gene therapy is also projected to offer promising growth prospects for industry players. Many biopharmaceutical companies are channeling resources into the development of new products. For example, Ori Biotech secured over USD 100.0 million in Series B funding in January 2022 to launch an innovative platform for cell and gene therapy development, enabling a swift progression from pre-commercialization to full market entry.

Get a preview of the latest developments in the Global Gene Therapy Market! Download your FREE sample PDF today and explore key data and trends

Regional Overview
In 2023, North America led the global gene therapy market, capturing a revenue share of 18.95%. This dominance is expected to continue throughout the forecast period, both in terms of regulatory approvals and revenue generation. Strong investment in research and development by both established and emerging companies is anticipated to drive further market expansion in the region.

Leading Companies in the Gene Therapy Market:
The key players shaping the gene therapy landscape and holding significant market shares include:

  • Amgen Inc.
  • Novartis AG
  • F. Hoffmann-La Roche
  • Gilead Sciences, Inc.
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • Legend Biotech
  • BioMarin
  • uniQure N.V.
  • Merck & Co.
  • Sarepta Therapeutics, Inc.
  • Krystal Biotech, Inc.
  • CRISPR Therapeutics

Gather more insights about the market drivers, restrains and growth of the Gene Therapy Market

Canned Wines Market Supported by Growth of E-Commerce and Online Alcohol Sales

The global canned wines market was valued at USD 112.9 million in 2024 and is expected to grow at a compound annual growth rate (CAGR) of 11.1% from 2025 to 2030. The rising preference for portable, convenient, and single-serve beverage options—particularly among younger demographics—is one of the key drivers of market expansion. Additionally, the growing appeal of ready-to-drink (RTD) products, driven by fast-paced lifestyles and demanding work schedules, has significantly fueled demand in both developed and emerging economies. Activities such as weekend getaways, camping, and hiking are gaining popularity, further boosting sales of canned beverages, which offer ease of use and eliminate concerns like spillage or breakage associated with traditional bottles.

The shift toward health-conscious living, particularly in advanced markets such as the U.S. and Western Europe, has created strong growth prospects for the canned wines sector. Many canned wine products are crafted in lighter, lower-alcohol formats that align with wellness-oriented consumer habits. Shoppers increasingly seek beverages that support healthier living—those with fewer calories, minimal additives, and lower alcohol levels. The single-serve format of canned wines also allows for better control over alcohol intake, resonating with the trend toward mindful consumption. Furthermore, these products are typically more cost-effective than bottled wines due to their lower production and packaging expenses, making them especially appealing for casual consumption and budget-friendly occasions.

Environmental sustainability continues to be a key factor influencing consumer choices and driving market growth. Canned wines are often considered more environmentally friendly than their bottled counterparts, primarily due to the recyclability of aluminum cans. As awareness around plastic and glass waste grows, more consumers are gravitating toward products with reduced environmental impact. Aluminum cans are also lighter and more space-efficient, cutting down transportation emissions and overall carbon footprint—further supporting the shift toward eco-friendly alternatives.

The canned wine category has experienced a surge in innovation, with brands introducing a variety of product types including sparkling wines, wine spritzers, and unique blends. These innovations appeal to a broader audience by offering diverse flavor experiences in a user-friendly format. Trend-forward offerings like sangria, flavored wines, and wine-based cocktails are drawing in both new wine consumers and those looking for a more relaxed, casual option.

Get a preview of the latest developments in the Global Canned Wines Market! Download your FREE sample PDF today and explore key data and trends

Regional Insights
North America led the global canned wines market in 2024, accounting for 37.7% of total revenue. This dominance is largely attributed to rising wine consumption in the region and the widespread availability of canned wine options. Among younger and middle-income consumers in the U.S. and Canada, canned wines are seen as a cost-effective and accessible alternative to bottled wines. Their appeal lies in affordability, ease of use, and a trendy image that resonates with Millennial and Gen Z consumers. These younger demographics are particularly drawn to the convenience and sustainability that canned wines represent.

Key Players in the Canned Wines Market
The following companies hold significant market shares and are instrumental in shaping industry trends:

  • E. & J. Gallo Winery
  • Union Wine Company
  • Sans Wine Co.
  • Sula Vineyards Limited
  • SUNTORY HOLDINGS LIMITED
  • Canned Wine Co.
  • Maker Wine Company
  • Archer Roose Wines

Gather more insights about the market drivers, restrains and growth of the Canned Wines Market

U.S. Dialysis Centers Market Sees Expansion with Growing Investments in Dialysis Infrastructure

The U.S. dialysis centers market size is expected to reach USD 40.39 billion by 2030, based on a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 5.4% from 2025 to 2030. The high prevalence of End-Stage Renal Disease (ESRD) and favorable reimbursement are some of the key factors expected to boost growth. The expenditure on treatment is gradually rising due to the increasing prevalence of ESRD.

The availability of Medicare reimbursement for kidney disorder treatment is increasing the accessibility to the treatment. The Center for Medicare & Medicaid Services announced a new end-stage renal diseases treatment choice model for the maintenance & improvement in the reimbursement for chronic kidney disorder patients. The new model is encouraging the use of home-based treatment. In August 2022, the CMS expanded the eligibility for reimbursement for kidney disorder treatment. The expansion includes certain capital assets, mainly equipment used at home for treatment. This is increasing the accessibility to the services.

The patients need to travel to and fro the center for around 3 days per week, the proximity from the patient’s residence is generally an important criterion for the center of choice. Hence the launch of new facilities is a key strategic initiative undertaken by major players to increase their market share. For instance, in May 2021, U.S. Renal Care, Inc. inaugurated three new facilities, one in-center facility and two focusing on home therapies. This expanded the company’s presence in the Southwest Florida region.

The COVID-19 pandemic resulted in patients facing difficulty in having an access to treatment for end-stage renal disorder, requiring multiple sessions within a month. According to the national kidney foundation, 15.8% of the patients undergoing treatment for end-stage renal disease had COVID-19 infection. The federal government & service providers promoted home treatment. In June 2021, a new campaign innovative kidney care was launched by nine leading healthcare organizations for patient options for receiving home treatment.

Get a preview of the latest developments in the U.S. Dialysis Centers Market! Download your FREE sample PDF today and explore key data and trends

U.S. Dialysis Centers Market Report Highlights

  • Based on service, the in-center segment held the largest revenue share in 2024. This can be attributed to the need for assistance & care for the procedure, which can be facilitated better at the centers. The high preference for hemodialysis is also driving the market opportunity as it essentially requires center visits & assistance.
  • Based on dialysis type, hemodialysis dominated the market in 2024. This can be attributed to the preference for the segment by healthcare professionals & longer life expectancy for patients. However peritoneal dialysis is expected to have the fastest growth during the forecast period owing to the effective removal of toxic substances & high convenience of peritoneal dialysis enabling patients to independently have treatment at home.
  • Based on facility type, dialysis chains dominated the market in 2024. This can be attributed to the presence of such chains throughout the U.S. The availability of top-quality equipment and treatment at a lower cost compared to hospital-based facilities is driving the segment’s growth. In addition, the key players are acquiring independent facilities, resulting in most of the independent facilities being managed by chains.
  • The service providers and patients faced challenges since the onset of the COVID-19 pandemic, some of which are unique as compared to other health facilities and treatment groups. For instance, hemodialysis (HD) patients visit centers at least three times a week and during each session, the patients are exposed to all the patients concurrently receiving treatment in a particular session, and to healthcare personnel along with any additional exposure during their travel to and from the center.
  • Mergers & acquisitions and collaborations are being preferred by the key players, enabling them to have a competitive edge by adding value to their services. For Instance, in March 2022, Fresenius Medical Care announced a merger with InterWell Health and Cricket Health for facilitating better kidney disorder solutions.

List of Key Players in the U.S. Dialysis Centers Market

  • Fresenius Medical Care AG
  • S. Renal Care, Inc.
  • DaVita Inc.
  • Innovative Renal Care
  • DCI
  • SATELLITE HEALTHCARE
  • Northwest Kidney Centers
  • Centers for Dialysis Care
  • Rogosin Institute
  • Dialysis Care Center
  • USCF Health (The Regents of The University of California)
  • Rhode Island Hospital, Department of Health Rhode Island
  • University of Iowa Hospital & Clinics
  • Saint Anthony Hospital
  • Rush University Children’s Hospital

Gather more insights about the market drivers, restrains and growth of the U.S. Dialysis Centers Market

Obesity Treatment Market Driven by Government Initiatives to Curb Obesity Epidemic

The global obesity treatment market size is expected to reach USD 60.53 billion in 2030 and is anticipated to grow at a CAGR of 22.31% from 2025 to 2030. The upward trend in sedentary lifestyles, physical inactivity, and unhealthy food habits are the vital factors responsible for the high prevalence of obesity. According to the Institute of Health Metrics and Evaluation, about 30.0% of the global population is either obese or overweight.

Additionally, along with commercial availability of solutions for weight management, technological advancements introduced by the vertical players and supportive initiatives undertaken by the governments, create more awareness with regard to obesity and its impact on health. This is further driving the growth of the obesity treatment market.

There are various approaches for weight management such as diet, exercise, drugs, minimally invasive devices & implants, and surgeries. Amongst the prevalent drugs, the combination drugs hold the largest market share whereas satiety drugs that provide a feeling of fullness appear as the fastest-growing segment in the obesity treatment market.

In surgeries, gastric bypass procedures form the largest growing segment whereas the minimally invasive endoscopic procedure segment that involves surgical placement of implants and devices, such as satiety devices and gastric emptying devices, is the fastest-growing space.

Get a preview of the latest developments in the Obesity Treatment Market! Download your FREE sample PDF today and explore key data and trends

Intense competition in the private sector has driven advancements and innovation toward the development of the latest techniques for obesity treatment that are offered in private hospitals and clinics. As a result, the demand for minimally invasive procedures is swiftly increasing. In addition, increasing awareness of obesity & the associated diseases and the commercial availability of weight management solutions is propelling the obesity treatment market.

Obesity Treatment Market Report Highlights

  • Based on drug class, the industry has been categorized into GLP-1 receptor agonists, lipase inhibitors, appetite suppressants, and other drug classes
  • Based on the route of administration, the obesity treatment market has been categorized into parenteral and oral
  • Based on distribution channels, the market has been categorized into hospital pharmacies, retail pharmacies, and others.
  • The other pharmacies are expected to grow at a considerable growth of over the forecast period
  • North America obesity treatment market dominated the global industry with a revenue share of 73.39% in 2024

Key Obesity Treatment Company Insights

Some prominent players in the global market are Novo Nordisk A/S, Rhythm Pharmaceuticals, Inc., Gelesis, Rhythm Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The market is shaped by mergers, acquisitions, and partnerships, along with significant investments in research & development to address unmet needs and expand treatment options.

Product innovation and regulatory approvals are key strategies for leading companies in the obesity treatment market to maintain a competitive edge. Established players focus on developing advanced therapies, such as next-generation GLP-1 receptor agonists and oral weight-loss drugs, while securing regulatory approvals to expand market reach. Meanwhile, emerging companies are targeting niche areas, including personalized obesity treatments and novel drug delivery mechanisms, to address unmet needs.

List of Key Players in Obesity Treatment Market

  • Novo Nordisk A/S
  • GlaxoSmithKline plc
  • VIVUS LLC
  • Currax Pharmaceuticals
  • Boehringer Ingelheim International GmbH
  • Rhythm Pharmaceuticals, Inc.
  • Gelesis
  • Eli Lilly and Company

Gather more insights about the market drivers, restrains and growth of the Global Obesity Treatment Market

U.S. Women’s Health Market Growth in Health Supplements and Nutritional Products

The U.S. women’s health market size is estimated to reach USD 24.36 billion by 2030, expanding at a CAGR of 3.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of target diseases is a key driver for the growth of the market. With aging and the increasing prevalence of obesity, the prevalence of osteoarthritis is anticipated to grow. Some of the major factors responsible for hormonal imbalance in women include changes in dietary habits, stress, and consumption of alcohol, which can cause fertility issues. Ovulation problems, polycystic ovarian syndrome (PCOS), and endometriosis are major factors responsible for infertility.

The rise in public funding for family planning services is further driving the market growth. In the U.S., approximately 45% of pregnancies are estimated to be unwanted every year. Despite advancements in contraceptive technology and increased R&D spending on contraceptives, the rate of unplanned pregnancies in the U.S. has remained unchanged for decades. This has increased the economic burden on low-income families that do not have easy access to modern and more effective methods of contraception. Hence, federal & state governments are actively working toward improving family planning services and access to modern contraceptives. For instance, in 2019, the U.S. government provided USD 608 million in funding to UNFPA for family planning & reproductive health development.

Moreover, child marriages are most common in underdeveloped and developing economies, often leading to early and unplanned pregnancies. There is a lack of awareness about contraceptives, which amplifies the severity of the problem. According to UNICEF, child marriages decreased by 15% in the past decade. However, the number has not decreased over the years in the U.S. because laws in certain U.S. states allow marriages before 18 years. However, efforts to address child marriage and its impact on women’s health are being undertaken in the country, which involve advocating for policy changes, promoting girls’ education, raising awareness about the negative consequences of child marriage, and providing support services for affected girls and women.

Get a preview of the latest developments in the U.S. Women’s Health Market! Download your FREE sample PDF today and explore key data and trends

Furthermore, key players involved in developing and formulating various therapeutics are focusing on collaborations and partnerships to develop novel drugs and maintain their competitive position in the market. For instance, in October 2022, Solera Health announced the launch of first-of-its-kind digital point solutions for women’s Health networks to address women’s health issues needs. Moreover, in November 2022, Sebela Pharmaceuticals announced the launch of a new division fully dedicated to women’s health.

U.S. Women’s Health Market Report Highlights

  • Based on drug, the Prolia drug segment held the largest revenue share in 2024 and is anticipated to grow at the fastest CAGR over the forecast period owing to the wide adoption of the drug with very less side effects
  • Based on application, the contraceptives segment is expected to showcase the fastest CAGR over the forecast period, owing to an increase in awareness about family planning
  • Based on age, the others age segment dominated the U.S. women’s health industry in 2024, due to the rising concerns of fertility, such as endometriosis, hormonal infertility, and PCOS in this age group
  • Based on distribution channel, the hospital pharmacy segment dominated the market in 2024 due to the high stock and availability of women’s health therapeutics in the hospital pharmacies
  • Key market players are constantly focusing on product launches and geographical expansion to maintain their presence

List of Key Players in U.S. Women’s Health Market

  • AbbVie, Inc.
  • Bayer AG
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Agile Therapeutics
  • Amgen, Inc.
  • Apothecus Pharmaceutical Corp.
  • Eli Lilly and Company
  • Ferring B.V.

Gather more insights about the market drivers, restrains and growth of the U.S. Women’s Health Market

Design a site like this with WordPress.com
Get started